LRRC32 and neoplasm: GARP is an emerging target for tumor therapy; therefore, further studies on the dynamic regulation of GARP and related pathological function will provide a deeper understanding of the mechanism of ATL progression and further lead to therapeutic efficacy in targeting activated Tregs in other cancer types.